Literature DB >> 29636974

The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.

Pascal Vranckx1, Marco Valgimigli2, Hein Heidbuchel3.   

Abstract

Vitamin K antagonists (VKAs) such as warfarin are the most commonly prescribed oral anticoagulants worldwide. However, factors affecting the pharmacokinetics of VKAs, such as food and drugs, can cause deviations from their narrow therapeutic window, increasing the bleeding or thrombosis risk and complicating their long-term use. The use of direct oral anticoagulants (DOACs) offers a safer and more convenient alternative to VKAs. However, it is important to be aware that plasma levels of DOACs are affected by drugs that alter the cell efflux transporter P-glycoprotein and/or cytochrome P450. In addition to these pharmacokinetic-based interactions, DOACs have the potential for pharmacodynamic interaction with antiplatelet agents and non-steroidal anti-inflammatory drugs. This is an important consideration in patient groups already at high risk of bleeding, such as patients with renal impairment.

Entities:  

Keywords:  Apixaban; dabigatran; direct oral anticoagulants; drug—drug interactions; edoxaban; rivaroxaban; vitamin K antagonists; warfarin

Year:  2018        PMID: 29636974      PMCID: PMC5889806          DOI: 10.15420/aer.2017.50.1

Source DB:  PubMed          Journal:  Arrhythm Electrophysiol Rev        ISSN: 2050-3369


  81 in total

1.  Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.

Authors:  Hamim Zahir; Nobuko Matsushima; Abdel-Baset Halim; Ling He; George Zhang; Frank Lee; Valerie Worland; Jeanne Mendell
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

2.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Authors:  Christopher P Cannon; Deepak L Bhatt; Jonas Oldgren; Gregory Y H Lip; Stephen G Ellis; Takeshi Kimura; Michael Maeng; Bela Merkely; Uwe Zeymer; Savion Gropper; Matias Nordaby; Eva Kleine; Ruth Harper; Jenny Manassie; James L Januzzi; Jurrien M Ten Berg; P Gabriel Steg; Stefan H Hohnloser
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

3.  Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Authors:  Antonio L Dans; Stuart J Connolly; Lars Wallentin; Sean Yang; Juliet Nakamya; Martina Brueckmann; Michael Ezekowitz; Jonas Oldgren; John W Eikelboom; Paul A Reilly; Salim Yusuf
Journal:  Circulation       Date:  2012-12-27       Impact factor: 29.690

4.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

5.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

Authors:  Jonas Oldgren; Andrzej Budaj; Christopher B Granger; Yasser Khder; Juliet Roberts; Agneta Siegbahn; Jan G P Tijssen; Frans Van de Werf; Lars Wallentin
Journal:  Eur Heart J       Date:  2011-05-07       Impact factor: 29.983

6.  Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery.

Authors:  Dino Kröll; Guido Stirnimann; Andreas Vogt; Desirée Lin Lee Lai; Yves Michael Borbély; Julia Altmeier; Sabine Schädelin; Daniel Candinas; Lorenzo Alberio; Philipp C Nett
Journal:  Br J Clin Pharmacol       Date:  2017-03-09       Impact factor: 4.335

Review 7.  Warfarin and its interactions with foods, herbs and other dietary supplements.

Authors:  Edith A Nutescu; Nancy L Shapiro; Sonia Ibrahim; Patricia West
Journal:  Expert Opin Drug Saf       Date:  2006-05       Impact factor: 4.250

8.  Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.

Authors:  Jeanne Mendell; Robert J Noveck; Minggao Shi
Journal:  J Cardiovasc Pharmacol       Date:  2012-10       Impact factor: 3.105

9.  Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.

Authors:  Greg Flaker; Renato D Lopes; Elaine Hylek; Daniel M Wojdyla; Laine Thomas; Sana M Al-Khatib; Renee M Sullivan; Stefan H Hohnloser; David Garcia; Michael Hanna; John Amerena; Veli-Pekka Harjola; Paul Dorian; Alvaro Avezum; Matyas Keltai; Lars Wallentin; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2014-10-14       Impact factor: 24.094

10.  Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.

Authors:  Dagmar Kubitza; Michael Becka; Wolfgang Mück; Jöern Krätzschmar
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

View more
  28 in total

1.  Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness.

Authors:  Cathy R Fulton; Marelize Swart; Thomas De Luca; Stephanie N Liu; Kimberly S Collins; Zeruesenay Desta; Brandon T Gufford; Michael T Eadon
Journal:  J Nurse Pract       Date:  2018-11-02       Impact factor: 0.767

Review 2.  Potential Drug Interactions Between Cannabinoids and Its Derivatives and Oral Anticoagulants.

Authors:  McKenzie Paduch; Angela R Thomason
Journal:  Hosp Pharm       Date:  2021-01-09

3.  Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies.

Authors:  Rushikesh Potdar; Benjamin A Gartrell; Robert Given; Lawrence Karsh; Jeffrey Frankel; Karen Nenno; Kris O'MalleyLeFebvre; Amitabha Bhaumik; Sharon McCarthy; Tracy McGowan; Christopher Pieczonka
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

4.  Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation.

Authors:  Hisham A Badreldin; Jahad Alghamdi; Omar Alshaya; Abdulmajeed Alshehri; Lamya Alreshoud; Renad Altoukhi; Senthilvel Vasudevan; Wesam W Ismail; Mohamed Salih Aziz Mohamed
Journal:  Int J Gen Med       Date:  2020-07-22

5.  Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.

Authors:  Kevin Hill; Ewa Sucha; Emily Rhodes; Marc Carrier; Amit X Garg; Ziv Harel; Gregory L Hundemer; Edward G Clark; Greg Knoll; Eric McArthur; Manish M Sood
Journal:  JAMA Intern Med       Date:  2020-08-01       Impact factor: 21.873

6.  Primary Care Provider Counseling Practices about Adverse Drug Reactions and Interactions in Croatia.

Authors:  Nikola Raguz Lucic; Jelena Jakab; Martina Smolic; Ana-Maria Milas; Tea Omanovic Kolaric; Vjera Nincevic; Kristina Bojanic; Kristina Kralik; Maja Miskulin; George Y Wu; Robert Smolic
Journal:  J Clin Med       Date:  2018-08-22       Impact factor: 4.241

7.  When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics.

Authors:  Jaap Seelig; Ron Pisters; Martin E Hemels; Menno V Huisman; Hugo Ten Cate; Marco Alings
Journal:  Vasc Health Risk Manag       Date:  2019-09-17

8.  Mortality in relation to presence and type of oral antithrombotic agent among adult trauma patients: a single-center retrospective cohort study.

Authors:  Jonathan B Yuval; Karry J Felix; Jonathan Demma; Haytem Awissat; Asaf Kedar; Daniel J Weiss; Alon J Pikarsky; Ora Paltiel; Irena Hamdi-Levi; Yosef Kalish; Miklosh Bala
Journal:  Eur J Trauma Emerg Surg       Date:  2020-07-05       Impact factor: 3.693

9.  Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min.

Authors:  Ophelia Yin; Tarundeep Kakkar; Anil Duggal; Masakatsu Kotsuma; Minggao Shi; Hans Lanz; Michael A Grosso
Journal:  Clin Pharmacol Drug Dev       Date:  2021-12-07

10.  Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database.

Authors:  Kazuyo Shimada; Shiori Hasegawa; Satoshi Nakao; Ririka Mukai; Sayaka Sasaoka; Natsumi Ueda; Yamato Kato; Junko Abe; Takayuki Mori; Tomoaki Yoshimura; Yasutomi Kinosada; Mitsuhiro Nakamura
Journal:  Int J Med Sci       Date:  2019-09-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.